The identification of functionally distinct macrophage subpopulations and the metabolic-immune-epigenetic axis involving APOA2 provides novel mechanistic insights into HCC pathogenesis and identifies genes and signaling axes whose pharmacological inhibition can reverse immunosuppression and block HCC progression for precision intervention strategies. This evidence concerns the gene APOA2 and hepatocellular carcinoma.